ReviewGenes2019
Next-Generation Technologies and Strategies for the Management of Retinoblastoma.
Review in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Management of Retinoblastoma: A Challenge in Pediatric Ophthalmology.Life (Basel, Switzerland) · 2026Review
- A Comprehensive Review of the Epidemiology, Pathophysiology, Risk Factors, and Treatment Strategies for Retinoblastoma.Diseases (Basel, Switzerland) · 2025Review
- Genetics of Retinoblastoma: An Overview and Significance of Genetic Testing in Clinical Practice.Genes · 2025Review
- LncRNA LOXL1-AS1 promotes proliferation and invasion and inhibits apoptosis in retinoblastoma by regulating the MAPK signaling pathway.Molecular and cellular biochemistry · 2024Article
- Transcriptome analysis reveals molecularly distinct subtypes in retinoblastoma.Scientific reports · 2023Article
- Genetics in ophthalmology: molecular blueprints of retinoblastoma.Human genomics · 2023Review
- Retinoblastoma: emerging concepts in genetics, global disease burden, chemotherapy outcomes, and psychological impact.Eye (London, England) · 2023Review
- PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma.Frontiers in oncology · 2023Article
- Application Progress of High-Throughput Sequencing in Ocular Diseases.Journal of clinical medicine · 2022Review
- pRB-Depleted Pluripotent Stem Cell Retinal Organoids Recapitulate Cell State Transitions of Retinoblastoma Development and Suggest an Important Role for pRB in Retinal Cell Differentiation.Stem cells translational medicine · 2022Article
- Applications of Non-Coding RNAs in Patients With Retinoblastoma.Frontiers in genetics · 2022Review
- Long non-coding RNA PROX1-AS1 knockdown upregulates microRNA-519d-3p to promote chemosensitivity of retinoblastoma cells via targeting SOX2.Cell cycle (Georgetown, Tex.) · 2021Article
- Ocular safety of repeated intravitreal injections of Carboplatin and Digoxin: A preclinical study on the healthy rabbits.Pharmacology research & perspectives · 2021Article
- ZNRD1-AS1 knockdown alleviates malignant phenotype of retinoblastoma through miR-128-3p/BMI1 axis.American journal of translational research · 2021Article
- Tumor-specific lytic path "hyperploid progression mediated death": Resolving side effects through targeting retinoblastoma or p53 mutant.World journal of clinical oncology · 2020Article
- Downregulation of microRNA-320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3.Experimental and therapeutic medicine · 2020Article
- Long non-coding RNA CASC9 promotes the progression of retinoblastoma via interacting with miR-145-5p.Cell cycle (Georgetown, Tex.) · 2020Article
- Long noncoding RNAs as potential biomarkers in retinoblastoma: a systematic review and meta-analysis.Cancer cell international · 2020Review
- Liquid Biopsy and Ocular Tumors: A Review.Journal of current ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Retinoblastoma (RB) is an inherited retinal disorder (IRD) caused by the mutation in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.